Multiple myeloma and cardiovascular risk (a literature review)
Multiple myeloma is a plasma cell clonal malignancy that accounts for 10 % of hematological cancers. It predominantly affects elderly people; median age at diagnosis is 70 years. Consequently, many patients with MM have cardiovascular comorbidities or risk factors. MM can cause cardiac comorbidities...
Saved in:
Main Authors: | B. B. Samura, M. O. Panasenko, S. Ya. Dotsenko |
---|---|
Format: | Article |
Language: | English |
Published: |
Zaporizhzhia State Medical and Pharmaceutical University
2020-11-01
|
Series: | Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki |
Subjects: | |
Online Access: | http://pharmed.zsmu.edu.ua/article/view/216234/216815 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cardiovascular events after polychemotherapy of multiple myeloma: modern ways to diagnostics
by: B. B. Samura, et al.
Published: (2020-03-01) -
Value of P-selectin in the prognosis of cardiovascular events in patients with multiple myeloma
by: M. O. Panasenko, et al.
Published: (2022-08-01) -
Prognostic value of P-selectin and sST2 in patients with multiple myeloma
by: M. O. Panasenko, et al.
Published: (2022-11-01) -
Structural-geometric and functional indicators of the heart in patients with multiple myeloma after anti-tumor treatment and COVID-19
by: B. B. Samura, et al.
Published: (2025-03-01) -
Cariohemodynamics in patients with multiple myeloma depending on renal function
by: B. B. Samura, et al.
Published: (2019-12-01)